Engineered immune cells take aim at Hard-to-Treat leukemias
NCT ID NCT06345027
First seen Jan 05, 2026 · Last updated May 03, 2026 · Updated 18 times
Summary
This early-phase study tests a new type of cell therapy for people with certain leukemias (AML, B-cell, or T-cell) that have returned or not responded to standard treatments. The therapy uses the patient's own T cells, modified in the lab to recognize and attack cancer cells carrying the CD70 protein. The main goals are to find a safe dose and to see if the treatment can shrink the cancer.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LEUKEMIA, MYELOID, ACUTE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Texas Children's Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Methodist Hospital
Houston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.